Lipocine (LPCN) said Tuesday that LPCN 1148 has received fast track designation from the US Food and Drug Administration as a treatment for sarcopenia in patients with decompensated cirrhosis.
Sarcopenia is a debilitating complication in patients with decompensated cirrhosis, an end-stage liver disease.
The Fast Track program helps accelerate the development and expedite the review of products that are meant to treat serious diseases and for which there is an unmet medical need.
Price: 5.01, Change: +0.02, Percent Change: +0.34
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.